244 related articles for article (PubMed ID: 9684655)
1. Clinical implications of nosocomial gram-positive bacteremia and superimposed antimicrobial resistance.
Linden PK
Am J Med; 1998 May; 104(5A):24S-33S. PubMed ID: 9684655
[TBL] [Abstract][Full Text] [Related]
2. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group.
Smith TL; Pearson ML; Wilcox KR; Cruz C; Lancaster MV; Robinson-Dunn B; Tenover FC; Zervos MJ; Band JD; White E; Jarvis WR
N Engl J Med; 1999 Feb; 340(7):493-501. PubMed ID: 10021469
[TBL] [Abstract][Full Text] [Related]
3. [Analysis of the pathogenic characteristics of 162 severely burned patients with bloodstream infection].
Gong YL; Yang ZC; Yin SP; Liu MX; Zhang C; Luo XQ; Peng YZ
Zhonghua Shao Shang Za Zhi; 2016 Sep; 32(9):529-35. PubMed ID: 27647068
[TBL] [Abstract][Full Text] [Related]
4. Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: therapeutic realities and possibilities.
Michel M; Gutmann L
Lancet; 1997 Jun; 349(9069):1901-6. PubMed ID: 9217771
[TBL] [Abstract][Full Text] [Related]
5. Glycopeptide resistance in gram-positive pathogens.
Fraimow HS; Shlaes DM
Adv Exp Med Biol; 1995; 390():81-95. PubMed ID: 8718604
[No Abstract] [Full Text] [Related]
6. Optimizing antibiotic therapy of bacteremia and endocarditis due to staphylococci and enterococci: new insights and evidence from the literature.
Falcone M; Russo A; Venditti M
J Infect Chemother; 2015 May; 21(5):330-9. PubMed ID: 25813608
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy for gram-positive nosocomial sepsis.
Wood MJ
J Chemother; 1999 Dec; 11(6):446-52. PubMed ID: 10678786
[TBL] [Abstract][Full Text] [Related]
8. Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant gram-positive bacterial pathogens.
Jantausch BA; Deville J; Adler S; Morfin MR; Lopez P; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S164-71. PubMed ID: 14520142
[TBL] [Abstract][Full Text] [Related]
9. The emergence of decreased susceptibility to vancomycin in Staphylococcus epidermidis.
Garrett DO; Jochimsen E; Murfitt K; Hill B; McAllister S; Nelson P; Spera RV; Sall RK; Tenover FC; Johnston J; Zimmer B; Jarvis WR
Infect Control Hosp Epidemiol; 1999 Mar; 20(3):167-70. PubMed ID: 10100541
[TBL] [Abstract][Full Text] [Related]
10. Optimizing antimicrobial therapy for gram-positive bloodstream infections in patients on hemodialysis.
Pai AB; Pai MP
Adv Chronic Kidney Dis; 2006 Jul; 13(3):259-70. PubMed ID: 16815231
[TBL] [Abstract][Full Text] [Related]
11. Molecular epidemiology and clinical characteristics of hetero-resistant vancomycin intermediate Staphylococcus aureus bacteremia in a Taiwan Medical Center.
Lin SY; Chen TC; Chen FJ; Chen YH; Lin YI; Siu LK; Lu PL
J Microbiol Immunol Infect; 2012 Dec; 45(6):435-41. PubMed ID: 22749725
[TBL] [Abstract][Full Text] [Related]
12. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains.
Jones RN
Clin Infect Dis; 2006 Jan; 42 Suppl 1():S13-24. PubMed ID: 16323115
[TBL] [Abstract][Full Text] [Related]
13. The specter of glycopeptide resistance: current trends and future considerations.
Moellering RC
Am J Med; 1998 May; 104(5A):3S-6S. PubMed ID: 9684651
[TBL] [Abstract][Full Text] [Related]
14. Antimicrobial resistance in gram-positive bacteria.
Rice LB
Am J Med; 2006 Jun; 119(6 Suppl 1):S11-9; discussion S62-70. PubMed ID: 16735146
[TBL] [Abstract][Full Text] [Related]
15. Overview of resistant gram-positive pathogens in the surgical patient.
Rapp RP
Surg Infect (Larchmt); 2000; 1(1):39-47. PubMed ID: 12594908
[TBL] [Abstract][Full Text] [Related]
16. Management of gram-positive coccal bacteremia and hemodialysis.
Fitzgibbons LN; Puls DL; Mackay K; Forrest GN
Am J Kidney Dis; 2011 Apr; 57(4):624-40. PubMed ID: 21333430
[TBL] [Abstract][Full Text] [Related]
17. Teicoplanin in the treatment of serious infection.
Schaison G; Graninger W; Bouza E
J Chemother; 2000 Nov; 12 Suppl 5():26-33. PubMed ID: 11131961
[TBL] [Abstract][Full Text] [Related]
18. New antibiotic agents for bloodstream infections.
Vergidis PI; Falagas ME
Int J Antimicrob Agents; 2008 Nov; 32 Suppl 1():S60-5. PubMed ID: 18723329
[TBL] [Abstract][Full Text] [Related]
19. [Daptomycin therapy in patients with bacteremia].
Llinares P; Iribarren JA
Enferm Infecc Microbiol Clin; 2012 Feb; 30 Suppl 1():17-25. PubMed ID: 22541971
[TBL] [Abstract][Full Text] [Related]
20. A therapeutic benefit of daptomycin against glycopeptide-resistant gram-positive cocci bloodstream infections under neutropenia.
Matsuda K; Koya J; Toyama K; Ikeda M; Arai S; Nakamura F; Okugawa S; Moriya K; Kurokawa M
J Infect Chemother; 2017 Nov; 23(11):788-790. PubMed ID: 28743428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
